{
    "clinical_study": {
        "@rank": "50481", 
        "brief_summary": {
            "textblock": "DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most\n      patients with hypertrophic cardiomyopathy (HCM).  Notably, when pacing is temporarily\n      discontinued, the beneficial effects of pacing are evident in sinus rhythm.  The long term\n      results of this novel therapy are, however, uncertain.  We propose (1) to record the\n      hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing\n      continues to be necessary in patients who have had a substantial relief of their LVOT\n      obstruction.  Patients who have had >50% reduction in LVOT pressure gradients will be\n      randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats\n      per minute (DDD switched off), and reevaluated after a six-month period."
        }, 
        "brief_title": "Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy", 
        "completion_date": "May 2000", 
        "condition": "Cardiomyopathy, Hypertrophic", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Hypertrophic", 
                "Hypertrophy", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most\n      patients with hypertrophic cardiomyopathy (HCM).  Notably, when pacing is temporarily\n      discontinued, the beneficial effects of pacing are evident in sinus rhythm.  The long term\n      results of this novel therapy are, however, uncertain.  We propose (1) to record the\n      hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing\n      continues to be necessary in patients who have had a substantial relief of their LVOT\n      obstruction.  Patients who have had >50% reduction in LVOT pressure gradients will be\n      randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats\n      per minute (DDD switched off), and reevaluated after a six-month period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Group 1:\n\n        HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at\n        the NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms.\n\n        Group 2:\n\n        HCM patients selected from Group 1 who at the follow-up cardiac catheterization are\n        demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest\n        and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT\n        obstruction (greater than 50% reduction in LVOT gradient).\n\n        Patient who have developed a heart block will be excluded from group 2.\n\n        Females must have a negative pregnancy test."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001530", 
            "org_study_id": "960059", 
            "secondary_id": "96-H-0059"
        }, 
        "keyword": [
            "Cardiac Hypertrophy", 
            "Drug-Refractory", 
            "Hemodynamic Benefits", 
            "Obstruction", 
            "Pacemaker Therapy", 
            "Hypertrophic Cardiomyopathy"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Heart, Lung and Blood Institute (NHLBI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "3181176", 
                "citation": "McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J. 1988 Aug;9(8):893-8."
            }, 
            {
                "PMID": "1350522", 
                "citation": "Fananapazir L, Cannon RO 3rd, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. 1992 Jun;85(6):2149-61."
            }, 
            {
                "PMID": "7994815", 
                "citation": "Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994 Dec;90(6):2731-42."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001530"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1996", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "National Heart, Lung and Blood Institute (NHLBI)": "38.985 -77.095"
    }
}